🔬 HistoSonics acquired for $2.25B

HistoSonics has sold a majority stake to a consortium of investors, including Bezos Expeditions, valuing the company at $2.25 billion.

Why it matters to oncology: The acquisition bolsters HistoSonics' capacity to advance non-invasive sonic beam therapy, targeting liver, kidney, and pancreatic tumors.

• With FDA De Novo clearance, their Edison system has shown a 90% local control rate for liver tumors, offering a promising treatment breakthrough.

The financials: The strategic investment enhances R&D and global expansion, with support from leading investors like K5 Global and Wellington Management.

• The backing provides the resources needed to scale clinical trials and market access.

What they're saying: "This is one of those rare moments where science, execution, and opportunity align," said Bryan Baum, K5 Global co-founder.

• CEO Mike Blue emphasized the transformative potential of their technology in global healthcare.

What's next: HistoSonics is enrolling patients in trials for various cancers and plans to expand into prostate cancer.

• The goal is to establish histotripsy as a non-invasive option for a wide range of solid tumors.